Portfolio
Corner Office
Culture
Premium
Opinion
Research
Video
Innovation
Menu
Subscribe
Sign In
Register
Portfolio
Corner Office
Culture
Premium
Opinion
Research
Video
Innovation
Search Query
Submit Search
Show Search
Actavis
Corner Office
Golden Parachutes Leave Investors Fearing Conflict of Interest
Rising change-in-control payments can prompt executives to push for a merger that may not benefit shareholders, critics say.
Jeff Ostrowski
May 17, 2016
Portfolio
Allergan-Pfizer Merger Gives Pharma a Growth Injection
The $160 billion all-stock deal is the largest-ever tax inversion and pharmaceutical sector merger.
Anne Szustek
December 16, 2015
Portfolio
Daily Agenda: Gravity Returns to Chinese Stock Market
Germany’s finance minister muses on euro zone unified financial authority; Teva announces acquisition of Allergan’s generic drug business.
Andrew Barber
July 27, 2015
Premium
Funds Benefit from Merger-Happy Health Care Stocks
Viking Global, Glenview Capital and Visium profit as stocks like Actavis, Anthem and Cigna rise on takeover fever.
Stephen Taub
June 23, 2015
Premium
Tiger Bloc’s Biggest Holdings: Actavis, CDK and JD.com
Group of 50 Tiger Cubs, Seeds and Grandcubs often invest in many of the same stocks. The big winner: Irish drugmaker Actavis.
Stephen Taub
June 4, 2015
Portfolio
The Morning Brief: Snapchat on the Road to Raising $650 Million
Stephen Taub
June 1, 2015
Premium
Viking Global Breaks with Tiger Cubs and Bets on Health Care
The hedge fund firm leaves tech and Internet to others, goes long on pharma and biotech, with some drugstores thrown in.
Stephen Taub
April 30, 2015
Premium
Conatus Capital Raises Funds for Long-Only Fund
Hurt last year by short trades like a number of other Tiger-related funds, the firm, with close ties to Lone Pine Capital, is going long.
Stephen Taub
April 22, 2015
Premium
Lone Pine on the Double-Edged Sword of Low Rates
Stephen Mandel, Jr.’s firm tries to balance negatives of stretched valuations against positives of companies using balance sheets to acquire.
Stephen Taub
April 15, 2015
Portfolio
Actavis CEO Brent Saunders Has a Vision for Growth
Once Actavis completes its merger with Allergan, CEO Brenton Saunders will need to focus on getting the two companies’ cultures and strategies on the same page.
Anne Szustek
March 12, 2015
